Literature DB >> 22933665

Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.

Elena Capel1, Glòria Martrus1, Mariona Parera1, Bonaventura Clotet1, Miguel Angel Martínez1.   

Abstract

The rapid spread of human immunodeficiency virus type 1 (HIV-1) in humans has been accompanied by continuous extensive genetic diversification of the virus. The aim of this study was to investigate the impact of HIV-1 diversification on HIV-1 replication capacity (RC) and mutational robustness. Thirty-three HIV-1 protease sequences were amplified from three groups of viruses: two naïve sample groups isolated 15 years apart plus a third group of protease inhibitor-(PI) resistant samples. The amplified proteases were recombined with an HXB2 infectious clone and RC was determined in MT-4 cells. RC was also measured in these three groups after random mutagenesis in vitro using error-prone PCR. No significant RC differences were observed between recombinant viruses from either early or recent naïve isolates (P = 0.5729), even though the proteases from the recent isolates had significantly lower sequence conservation scores compared with a subtype B ancestral sequence (P<0.0001). Randomly mutated recombinant viruses from the three groups exhibited significantly lower RC values than the corresponding wild-type viruses (P<0.0001). There was no significant difference regarding viral infectivity reduction between viruses carrying randomly mutated naïve proteases from early or recent sample isolates (P = 0.8035). Interestingly, a significantly greater loss of RC was observed in the PI-resistant protease group (P = 0.0400). These results demonstrate that protease sequence diversification has not affected HIV-1 RC or protease robustness and indicate that proteases carrying PI resistance substitutions are less robust than naïve proteases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933665     DOI: 10.1099/vir.0.045492-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  HIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding.

Authors:  Maria Nevot; Ana Jordan-Paiz; Glòria Martrus; Cristina Andrés; Damir García-Cehic; Josep Gregori; Sandra Franco; Josep Quer; Miguel Angel Martinez
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

2.  Social, Epidemiological, and Virological Characteristics from Peruvian Subjects Living with HIV-1/AIDS with Different Sexual Risk Behavior.

Authors:  Carlos Augusto Yabar; Giovanny Francesco Vilcarino; Susan Espetia; Fiorela Lujan; Andres Vásquez-Domínguez; Mariela Yaya; Maribel Acuña; Daniel Santos; Edgardo Mamani; Rafael Rodriguez-Bayona; Javier Salvatierra; George Obregon; Soledad Romero; Fany Cardenas; Pablo Lopez; Vanessa Rivera-Amill
Journal:  AIDS Res Hum Retroviruses       Date:  2021-11-22       Impact factor: 1.723

3.  Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture.

Authors:  Gloria Martrus; Maria Nevot; Cristina Andres; Bonaventura Clotet; Miguel Angel Martinez
Journal:  Retrovirology       Date:  2013-07-25       Impact factor: 4.602

4.  Epistasis as a determinant of the HIV-1 protease's robustness to mutation.

Authors:  Elena Capel; Mariona Parera; Miguel Angel Martinez
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

5.  Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence.

Authors:  Claudia Alteri; Lavinia Fabeni; Rossana Scutari; Giulia Berno; Domenico Di Carlo; Caterina Gori; Ada Bertoli; Alessandra Vergori; Ilaria Mastrorosa; Rita Bellagamba; Cristina Mussini; Manuela Colafigli; Francesco Montella; Alfredo Pennica; Claudio Maria Mastroianni; Enrico Girardi; Massimo Andreoni; Andrea Antinori; Valentina Svicher; Francesca Ceccherini-Silberstein; Carlo Federico Perno; Maria Mercedes Santoro
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.